Search

Your search keyword '"Bukur, Thomas"' showing total 19 results
Start Over Author "Bukur, Thomas" Search Limiters Full Text
19 results on '"Bukur, Thomas"'

1. Transcriptional reprogramming by mutated IRF4 in lymphoma

Author

Schleussner, Nikolai, Cauchy, Pierre, Franke, Vedran, Giefing, Maciej, Fornes, Oriol, Vankadari, Naveen, Assi, Salam A., Costanza, Mariantonia, Weniger, Marc A., Akalin, Altuna, Anagnostopoulos, Ioannis, Bukur, Thomas, Casarotto, Marco G., Damm, Frederik, Daumke, Oliver, Edginton-White, Benjamin, Gebhardt, J. Christof M., Grau, Michael, Grunwald, Stephan, Hansmann, Martin-Leo, Hartmann, Sylvia, Huber, Lionel, Kärgel, Eva, Lusatis, Simone, Noerenberg, Daniel, Obier, Nadine, Pannicke, Ulrich, Fischer, Anja, Reisser, Anja, Rosenwald, Andreas, Schwarz, Klaus, Sundararaj, Srinivasan, Weilemann, Andre, Winkler, Wiebke, Xu, Wendan, Lenz, Georg, Rajewsky, Klaus, Wasserman, Wyeth W., Cockerill, Peter N., Scheidereit, Claus, Siebert, Reiner, Küppers, Ralf, Grosschedl, Rudolf, Janz, Martin, Bonifer, Constanze, and Mathas, Stephan

Published
2023
Full Text
View/download PDF

8. Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model

Author

Schrörs, Barbara, primary, Boegel, Sebastian, additional, Albrecht, Christian, additional, Bukur, Thomas, additional, Bukur, Valesca, additional, Holtsträter, Christoph, additional, Ritzel, Christoph, additional, Manninen, Katja, additional, Tadmor, Arbel D., additional, Vormehr, Mathias, additional, Sahin, Ugur, additional, and Löwer, Martin, additional

Published
2020
Full Text
View/download PDF

9. A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice

Author

Salomon, Nadja, primary, Vascotto, Fulvia, additional, Selmi, Abderaouf, additional, Vormehr, Mathias, additional, Quinkhardt, Juliane, additional, Bukur, Thomas, additional, Schrörs, Barbara, additional, Löewer, Martin, additional, Diken, Mustafa, additional, Türeci, Özlem, additional, Sahin, Ugur, additional, and Kreiter, Sebastian, additional

Published
2020
Full Text
View/download PDF

10. Additional file 2: of HLA and proteasome expression body map

Author

Boegel, Sebastian, LĂśwer, Martin, Bukur, Thomas, Sorn, Patrick, Castle, John, and Ugur Sahin

Abstract

Figure S1. HLA Class I (A) and II (B) expression body map including anatomical substructures. Figure S2. Immunological characterization of brain samples. Figure S3. Locus specific expression of classical HLA class I (A) and class II (B) genes across all examined tissues. Figure S4. Expression body map of the non-classical HLA Class I genes. (A) HLA-E transcripts are ubiquitously expressed in all tissues. Figure S5. Expression of constitutive proteasome versus immunoproteasome normalized with TPM. Figure S6. Correlation analysis of CIITA and HLA expression. Figure S7. Expression of constitutive proteasome, Immunoproteasome and its inducing cytokines. Figure S8. Expression of TAP1, TAP2 and PSMB9. (PPTX 5223Â kb)

Published
2018
Full Text
View/download PDF

12. A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice.

Author

Salomon, Nadja, Vascotto, Fulvia, Selmi, Abderaouf, Vormehr, Mathias, Quinkhardt, Juliane, Bukur, Thomas, Schrörs, Barbara, Löewer, Martin, Diken, Mustafa, Türeci, Özlem, Sahin, Ugur, and Kreiter, Sebastian

Subjects
T cells, RNA, VACCINES, MICE, RADIOTHERAPY, MAYER-Rokitansky-Kuster-Hauser syndrome, REJECTION (Psychology)
Abstract

Antigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8+ T cell-dependent manner by an RNA-LPX vaccine that encodes CD4+ T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8+ T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8+ T cell response and T cell memory. In the spleens of CD4 neoantigen-vaccinated mice, we found a high number of activated, poly-functional, Th1-like CD4+ T cells against ME1, the immunodominant CD4 neoantigen within the poly-neoantigen vaccine. LRT itself strongly increased CD8+ T cell numbers and clonal expansion. However, tumor infiltrates of mice treated with CD4 neoantigen vaccine/LRT, as compared to LRT alone, displayed a higher fraction of activated gp70-specific CD8+ T cells, lower PD-1/LAG-3 expression and contained ME1-specific IFNγ+ CD4+ T cells capable of providing cognate help. CD4 neoantigen vaccine/LRT treatment followed by anti-CTLA-4 antibody therapy further enhanced the efficacy with complete remission of gp70-negative CT26 tumors and survival of all mice. Our data highlight the power of combining synergistic modes of action and warrants further exploration of the presented treatment schema. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

13. Additional file 2: Figure S1. of TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression

Author

Scholtalbers, Jelle, Boegel, Sebastian, Bukur, Thomas, Byl, Marius, Goerges, Sebastian, Sorn, Patrick, Loewer, Martin, Ugur Sahin, and Castle, John

Subjects
virus diseases, digestive system diseases
Abstract

Virus identification. HBV is expressed in the liver carcinoma cell line PLC/PRF/5. (PPTX 180 kb)

Published
2015
Full Text
View/download PDF

16. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

Author

Castle, John C, primary, Loewer, Martin, additional, Boegel, Sebastian, additional, de Graaf, Jos, additional, Bender, Christian, additional, Tadmor, Arbel D, additional, Boisguerin, Valesca, additional, Bukur, Thomas, additional, Sorn, Patrick, additional, Paret, Claudia, additional, Diken, Mustafa, additional, Kreiter, Sebastian, additional, Türeci, Özlem, additional, and Sahin, Ugur, additional

Published
2014
Full Text
View/download PDF

17. HLA typing from RNA-Seq sequence reads

Author

Boegel, Sebastian, primary, Löwer, Martin, additional, Schäfer, Michael, additional, Bukur, Thomas, additional, de Graaf, Jos, additional, Boisguérin, Valesca, additional, Türeci, Özlem, additional, Diken, Mustafa, additional, Castle, John C, additional, and Sahin, Ugur, additional

Published
2012
Full Text
View/download PDF

18. A liposomal RNA vaccine inducing neoantigen-specific CD4+T cells augments the antitumor activity of local radiotherapy in mice

Author

Salomon, Nadja, Vascotto, Fulvia, Selmi, Abderaouf, Vormehr, Mathias, Quinkhardt, Juliane, Bukur, Thomas, Schrörs, Barbara, Löewer, Martin, Diken, Mustafa, Türeci, Özlem, Sahin, Ugur, and Kreiter, Sebastian

Abstract

ABSTRACTAntigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8+T cell-dependent manner by an RNA-LPX vaccine that encodes CD4+T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8+T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8+T cell response and T cell memory. In the spleens of CD4 neoantigen-vaccinated mice, we found a high number of activated, poly-functional, Th1-like CD4+T cells against ME1, the immunodominant CD4 neoantigen within the poly-neoantigen vaccine. LRT itself strongly increased CD8+T cell numbers and clonal expansion. However, tumor infiltrates of mice treated with CD4 neoantigen vaccine/LRT, as compared to LRT alone, displayed a higher fraction of activated gp70-specific CD8+T cells, lower PD-1/LAG-3 expression and contained ME1-specific IFNγ+CD4+T cells capable of providing cognate help. CD4 neoantigen vaccine/LRT treatment followed by anti-CTLA-4 antibody therapy further enhanced the efficacy with complete remission of gp70-negative CT26 tumors and survival of all mice. Our data highlight the power of combining synergistic modes of action and warrants further exploration of the presented treatment schema.

Published
2020
Full Text
View/download PDF

19. A liposomal RNA vaccine inducing neoantigen-specific CD4 + T cells augments the antitumor activity of local radiotherapy in mice.

Author

Salomon N, Vascotto F, Selmi A, Vormehr M, Quinkhardt J, Bukur T, Schrörs B, Löewer M, Diken M, Türeci Ö, Sahin U, and Kreiter S

Subjects
Animals, Antigens, Neoplasm genetics, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Female, Mice, Mice, Inbred BALB C, RNA, Cancer Vaccines
Abstract

Antigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8 + T cell-dependent manner by an RNA-LPX vaccine that encodes CD4 + T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8 + T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8 + T cell response and T cell memory. In the spleens of CD4 neoantigen-vaccinated mice, we found a high number of activated, poly-functional, Th1-like CD4 + T cells against ME1, the immunodominant CD4 neoantigen within the poly-neoantigen vaccine. LRT itself strongly increased CD8 + T cell numbers and clonal expansion. However, tumor infiltrates of mice treated with CD4 neoantigen vaccine/LRT, as compared to LRT alone, displayed a higher fraction of activated gp70-specific CD8 + T cells, lower PD-1/LAG-3 expression and contained ME1-specific IFNγ + CD4 + T cells capable of providing cognate help. CD4 neoantigen vaccine/LRT treatment followed by anti-CTLA-4 antibody therapy further enhanced the efficacy with complete remission of gp70-negative CT26 tumors and survival of all mice. Our data highlight the power of combining synergistic modes of action and warrants further exploration of the presented treatment schema., (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results